Zacks Investment Research disclosed Abbott Laboratories (NYSE:ABT), bumping its target to $47.00 earlier today
- Updated: September 20, 2016
Zacks Investment Research upped the price target of Abbott Laboratories (NYSE:ABT) to $47.00 stating a potential upside of 0.12%.
Yesterday Abbott Laboratories (NYSE:ABT) traded -0.24% lower at $41.89. The company’s 50-day moving average is $43.36 and its 200-day moving average is $41.15. The last stock close price is up 1.04% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 4,866,948 shares of the stock were exchanged, down from an average trading volume of 10,121,300
See Chart Below
Abbott Laboratories has a price-earnings ratio of 27.45 with a one year low of $36.00 and a one year high of $46.38 ABT’s total market value is presently $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 15 brokers have issued a research note on the company. The average stock price target is $46.73 with 6 brokers rating the stock a strong buy, 8 brokers rating the stock a buy, 6 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Abbott Laboratories (NYSE:ABT)
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products. Its Established Pharmaceutical Products segment's therapeutic area portfolio of products includes gastroenterology products, women's health products, and respiratory drugs and vaccines.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.